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Treatment-resistant depression (TRD) presents many challenges for both patients and physicians. This review aims to evaluate the current status of the field of TRD and reflects the main findings of a consensus meeting held in September 2009. Literature searches were also conducted using PubMed and EMBASE. Abstracts of the retrieved articles were reviewed independently by the authors for inclusion. Evaluation of the clinical evidence in TRD is complicated by the absence of a validated definition, and there is a need to move away from traditional definitions of remission based on severity of symptoms to one that includes normalisation of functioning. One potential way of improving treatment of TRD is through the use of predictive biomarkers and clinical variables. The advent of new treatments may also help by focusing on neurotransmitters other than serotonin. Strategies such as the switching of antidepressants, use of combination therapy with lithium, atypical antipsychotics and other pharmacological agents can improve outcomes, and techniques such as deep brain stimulation and vagus nerve stimulation have shown promising early results. Despite consistent advances in the pharmacotherapy of mood disorders in the last decade, high rates of TRD are still a challenging aspect of overall management.






Depression is one of the leading causes of disease burden worldwide, with a greater impact on health status than chronic systemic diseases such as angina or diabetes  ADDIN EN.CITE (Moussavi et al., 2007). Importantly, data on the incidence of major depressive disorder (MDD) in Europe, particularly treatment-resistant depression (TRD), are limited, although MDD is one of the most prevalent mental disorders (Figure 1)  ADDIN EN.CITE (Wittchen and Jacobi, 2005). Furthermore, MDD in Europe is often under-diagnosed and under-treated, for reasons including, among others, a lack of awareness, stigma, diagnostic problems and inadequate treatment  ADDIN EN.CITE (Arbabzadeh-Bouchez et al., 2002; Lecrubier, 2007). Even in patients who receive adequate treatment with an antidepressant, a large percentage of depressive episodes are associated with some degree of treatment resistance  ADDIN EN.CITE (Souery et al., 1999; Rush et al., 2006; Trivedi et al., 2006; Trivedi et al., 2009). In the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study, for example, approximately two-thirds of patients failed to achieve remission after the initial antidepressant therapy  ADDIN EN.CITE (Rush et al., 2006). The clinical importance of these figures is underscored by the fact that incomplete recovery or partial remission from a depressive episode is associated with serious personal, economic and psychosocial morbidity  ADDIN EN.CITE (Wells et al., 1989; Donohue and Pincus, 2007; Moussavi et al., 2007). Despite consistent advances in the pharmacotherapy of mood disorders in the last decade, high rates of TRD are still a challenging aspect of overall management. 

This review sought to examine the current status of the field of TRD in terms of disease awareness, treatment goals, treatment strategies, and future plans for the treatment of TRD.

Methodology
This review presents the main findings of a consensus meeting held in September 2009. The meeting was convened in order to discuss the unmet needs in the field of TRD and the current use of pharmacotherapy in the treatment of TRD. A supplemental search of the literature pertaining to TRD was also conducted using PUBMED and EMBASE. All searches were limited to English language and no date limits were applied to the searches. Searches were limited to the title/abstract fields. Published congress abstracts or posters were not included. Abstracts of the retrieved studies and relevant review articles were reviewed independently by both authors for inclusion in the article and any discrepancies resolved by discussion. Of the retrieved studies, only those pertaining to TRD and, where relevant, MDD were selected. Reference lists of review papers were searched for further publications.

Neurobiology and genetics of depression
Our understanding of the complex neurobiology of depression is still evolving. Three neurotransmitters have been identified as playing a key role in depression: dopamine, noradrenaline and serotonin (Figure 2). Although all three have been implicated in mood, emotion and cognitive function, they are also involved in other signs and symptoms of MDD. In particular, dopamine and noradrenaline are involved in motivational aspects of the disorder, whereas noradrenaline and serotonin are involved in symptoms of anxiety and irritability. Brain imaging studies show clear regional effects in MDD, with a small hippocampus and amygdala reported in some, although not all, imaging studies (Campbell and MacQueen, 2006). 

A genetic component to MDD is also evident, as indicated by twin, adoption and family studies (Lohoff, 2010). Indeed, MDD heritability of 37% has been demonstrated in a meta-analysis of five twin studies (Sullivan et al., 2000), whereas a meta-analysis of five family studies has shown a two- to three-fold increase in lifetime risk of developing MDD among first-degree relatives (Sullivan et al., 2000). Despite ongoing research using linkage and association studies and recent findings from genome-wide association studies, no single genetic variant has been identified to increase risk of depression (Lohoff, 2010). It is postulated that multiple genetic variants in conjunction with environmental factors are responsible for the development of MDD  ADDIN EN.CITE (Sullivan et al., 2000; Lohoff, 2010), and large-scale studies are required to further investigate the complex phenotype of MDD and identify pathways in its development. If genetic variants could be identified, these would prove to be invaluable in understanding the nature of depression, as well as targeting treatment, maximising response and minimising resistance. 

Recognising TRD
Current treatments of depression have largely been based on serendipitous observations of antidepressant effects of substances such as iproniazid (originally developed as a treatment for tuberculosis) or imipramine (originally developed as a treatment for schizophrenia) (Slattery et al., 2004).

Insights into the role of monoamine neurotransmitters in the actions of the first antidepressants led to a more targeted drug discovery process, resulting in drugs with improved side-effect profiles, such as selective serotonin reuptake inhibitors (SSRIs)  ADDIN EN.CITE (Richelson, 2003). These drug treatments, in conjunction with certain methods of psychotherapy, are effective at improving depressive symptomatology in many patients. However, they do not work for all patients; a sizeable minority do not respond, whereas others may experience only a partial response (Figure 3). Indeed, 17–21% of patients suffering from major depression have a poor outcome after 2 years, and 8–13% have a poor outcome even after 5 years of treatment (Winokur et al., 1993). More recently, the STAR*D study (n=3671) showed that remission rates (QIDS-SR16 score ≤5) are approximately 37% after first-line treatment with citalopram, decreasing to 31% for second-line, 14% for third-line and 13% for fourth-line treatment options (Warden et al., 2007). This leaves a group of non-responders often generally referred to as ‘treatment resistant’. This underserved population has had little hope of recovering from their debilitating disease. 

Due to the heterogeneity of TRD and lack of consensus on diagnostic criteria, an operational, validated and systematic definition for the condition is still lacking (Souery et al., 2006). Some patients considered to be treatment resistant may have been misdiagnosed or may have received inadequate treatment. This raises the question as to what constitutes ‘adequate’ treatment, in terms of drug dose, duration of therapy and compliance. Furthermore, consensus is required on the number of failures to adequate treatment that a patient must experience before they are considered to be treatment resistant. In Europe, the Committee for Medicinal Products for Human Use (CHMP) has stated that a patient is considered to be therapy resistant when consecutive treatment with two antidepressants of different classes (different mechanism of action), used for a sufficient length of time and at an adequate dose, fail to induce an acceptable effect (EMA, 2009). However, ‘sufficient’ and ‘adequate’ are not defined and consensus from the wider psychiatric community is still required. In addition, true pharmacological resistance needs to be distinguished from resistance due to ongoing somatic or psychosocial problems. 

Some staging models have been used for the definition of TRD, but further clinical validation is needed. The Massachusetts General Hospital staging method uses a quantitative approach based on the number of non-responses to adequate antidepressant treatment, outcome of optimisation strategies and need for electroconvulsive therapy (ECT) (Fava, 2003). The model, proposed by Thase and Rush, uses stages 1–5 to qualify the different levels of treatment resistance, based on the use of agents from different drug classes (Thase and Rush, 1997). The Maudsley Staging Method is a recent, multidimensional staging method that considers the number of failed treatments, as well as the severity and duration of the current depressive episode  ADDIN EN.CITE (Fekadu et al., 2009a). 

Many European countries have run national and regional awareness programmes for depression. The authors are aware that several of these initiatives have included a specific focus on MDD but, to date, they are not aware of national programmes primarily aimed at TRD. This may not be surprising, given the lack of an accepted, unified definition of TRD.

Clinical consequences of TRD
In a systematic review of nine outcomes studies (n=1279), including cases with highly probable TRD, the condition was shown to be highly recurrent, with up to 80% of patients who required multiple treatments experiencing relapse within 1 year of remission (Fekadu et al., 2009b). Similarly, a retrospective study of the records of 115 patients found that 50.4% of patients did not achieve remission at any time during their treatment  ADDIN EN.CITE (Petersen et al., 2005). Data from the STAR*D study have shown that there is a general increase in relapse rates and a decline in remission rates with each successive treatment step (Figure 4)  ADDIN EN.CITE (Warden et al., 2007; Rush et al., 2009). In patients with long-term MDD, the probability of recovery within 10 years was approximately 40% (Fekadu et al., 2009b) The clinical outcome of non-remitting patients has been shown to be worse than that of first-episode patients  ADDIN EN.CITE (Demyttenaere et al., 2008), and even those who achieve partial remission are at greatly increased risk of relapse, particularly in the first year (Paykel, 2008). 

In the absence of remission, MDD is associated with impairment in work, social and family life, as well as increased mortality  ADDIN EN.CITE (Mintz et al., 1992; Ansseau et al., 2009; Fekadu et al., 2009b). The risk of suicide may also be higher in patients who do not achieve remission. For example, of 145 patients followed up for an average of 15 years, only 20% had achieved maintained remission, whereas 7% had committed suicide (Kiloh et al., 1988). 

MDD is associated with disturbed sleep (Mendlewicz, 2009a). Circadian gene mutations are associated with circadian rhythm disorders (Mendlewicz, 2009b) and such disorders have been observed in patients with depression (Monteleone and Maj, 2008), which suggests a shared aetiology between circadian disruption and depression (Mendlewicz, 2009b). Indeed, polymorphisms in certain genes associated with circadian rhythm (e.g. CLOCK and TIMELESS) have been associated with susceptibility to mood disorder, and polymorphisms in several circadian rhythm genes have been observed in those with circadian rhythm abnormalities, such as insomnia in mania and middle or late insomnia in depression (Mendlewicz, 2009b). The exact mechanisms underlying this relationship are unclear but evidence is emerging that interventions able to resynchronise the circadian rhythm – including sleep deprivation, light therapy and pharmacotherapy, which specifically act on the endogenous clock system – have proven antidepressant effects  ADDIN EN.CITE (Monteleone and Maj, 2008; Mendlewicz, 2009b). Indeed, sleep deprivation can be effective in some patients with MDD, with an immediate onset of action, and can be used in conjunction with antidepressant therapy to produce short-term gains, although relapse is still common  ADDIN EN.CITE (Bauer et al., 2007). Further research into the role of sleep in the underlying pathophysiology and treatment of depression is warranted.

Defining patients as treatment resistant
Before initiating or altering existing treatment, it is critical to confirm the diagnosis of depression (i.e. an episode of primary MDD), re-evaluate the patient for medical or psychiatric comorbidity, identify concomitant medications that might have induced depression (e.g. beta-blockers) and ensure that patients have adhered to any existing treatment regimen. Another important question is the definition of an adequate antidepressant trial, defined as an appropriate drug given in a dosage and duration sufficient to produce a response (Thase, 2003). Nowadays, 4–6 weeks is considered to be an adequate trial period to see clinical response, although recent research suggests that longer periods (up to 8 or 12 weeks) may be needed to achieve remission (Fleck and Horwath, 2005). The concept of adequate dosage, however, is more difficult to determine. Clinically, it is defined either as the minimum dosage that will produce the expected effect or the maximum dosage that the patient can tolerate until the expected effect is achieved, although, within the therapeutic range, high doses of antidepressants generally increased the likelihood of response (Thase, 2003).

Treatment goals
In a now-classic analysis of depression, Kupfer and colleagues defined three phases that could be identified in the treatment strategy for major depression, namely acute, continuation and maintenance (Kupfer, 1991). Additionally, these phases can be considered as response, remission and recovery (Figure 5). When evaluating patients with MDD, it is important that validated scales are used to measure all these phases. For example, the Hamilton Depression Rating Scale (HAM-D) and the Montgomery–Åsberg Depression Rating Scale (MADRS) are often used to assess the degree of response after antidepressant treatment  ADDIN EN.CITE (Hamilton, 1960; Montgomery and Asberg, 1979). There is, however, a need for a move away from traditional definitions of remission, such as those based solely on HAM-D or MADRS scores. In particular, normalisation of functioning is an important part of remission that is rarely evaluated in clinical trials of antidepressant efficacy. As part of the Methods to Improve Diagnostic Assessment and Services (MIDAS) project, the association between level of severity of depressive symptoms and functional impairment was evaluated for its ability to predict patients' subjective evaluation of their remission status  ADDIN EN.CITE (Zimmerman et al., 2008). Psychiatric outpatients with depression (n=514) completed a questionnaire assessing their symptoms of depression, the level of impairment as a result of their depression, and their quality of life. The results showed large, statistically significant correlations between symptom severity, functional impairment and quality of life, and each variable was also significantly associated with remission status. Logistical regression analysis confirmed that each of the three variables was a significant, independent predictor of remission.

There is now a general consensus that remission is the gold standard and primary objective of depression treatment  ADDIN EN.CITE (Mendlewicz, 2008; Trivedi et al., 2009). Treatment during the acute phase of TRD should therefore focus on remission as the goal, whereas continuation therapy should focus on maintenance of remission and prevention of relapse (Nelson et al., 2008). It is important to manage patients’ expectations in this regard, increasing their awareness of appropriate treatment goals and highlighting the importance of social support and family influence in achieving those goals. Physicians should also be aware of potential barriers to treatment success, many of which reduce patients’ adherence to treatment. For example, perceived stigma and the patient’s view of depression can affect adherence (Sirey et al., 2001), whereas the nature of depression itself works against treatment success. Tolerability issues with antidepressants can also challenge treatment adherence and quality of life, jeopardising the chance of achieving remission (Kelly et al., 2008). It is important to distinguish treatment-emergent adverse events from residual depressive symptoms, signs of relapse or comorbidities. Side-effects should be managed appropriately, and communication between patient and physician is essential. Surprisingly, adherence has been shown to be higher in non-remitters compared with first-episode patients with MDD  ADDIN EN.CITE (Demyttenaere et al., 2008). In some regions of the world, another barrier to the effective treatment of TRD may be the under-utilization of community psychiatric care teams to treat these chronically unresponsive patients. 

Predictive markers of TRD
In an attempt to improve the diagnosis and treatment of TRD, many groups have searched for predictive factors. Data are sparse, however, and most predictive factors are currently theoretical. True biological markers for depression and treatment resistance would be invaluable and should continue to be the focus of research. In an analysis of 702 patients with MDD, of whom 356 were considered to be resistant to treatment, 11 variables were found to be associated with TRD (Table 1) (Souery et al., 1999). The most discriminative of these variables were found to be comorbid anxiety disorder, current suicidal risk, melancholic features and non-response to first antidepressant (lifetime) (Figure 6). A significant relationship between anxiety and TRD was also identified in the STAR*D study, in which 53% of patients were diagnosed with ‘anxious depression’  ADDIN EN.CITE (Trivedi et al., 2006). These patients had a significantly reduced chance of remission (OR=0.8; p<0.002), defined as a score of ≤5 on the Quick Inventory of Depressive Symptomatology Self Report (QIDS-SR). Similarly, patients with generalised anxiety disorder also had a significantly lower chance of remission (OR=0.80; p=0.03). Depression with melancholic features is also associated with poor outcomes, as well as more acute treatment steps and greater levels of treatment resistance (Rush et al., 2009), whereas patients with MDD with psychotic features are more likely to exhibit relapse than non-psychotic patients (Rothschild, 2003). Depression may also feature as a comorbid condition in patients with substance use disorders (Ostacher, 2007) or with chronic diseases such as diabetes or arthritis (Nelson et al., 2008). In cases such as these, MDD may act synergistically with the comorbid condition, each complicating and worsening the impact of the other.

Treating the patient with TRD
Research into the biological effects of antidepressant drugs has focused primarily on serotonin, with an acknowledgement that noradrenaline and dopamine play an important role in the pathophysiology of MDD and its symptoms  ADDIN EN.CITE (Nutt et al., 2007). Clinical trial data suggest, however, that drugs that enhance noradrenaline, dopamine or serotonin have similar efficacy for the treatment of depression. Indeed, dopaminergic and noradrenergic agents have demonstrated antidepressant activity in the absence of direct effects on serotonergic function, showing similar efficacy to both tricyclic antidepressants and serotonin reuptake inhibitors. With regard to specific symptoms, serotonergic antidepressants appear to be more effective in treating ‘negative’ symptoms, such as fear, anxiety and irritability, whereas antidepressants with dopaminergic or noradrenergic activity may be effective in treating the loss of positive affect (e.g. loss of motivation and capacity for enjoyment) (Figure 7). For example, the noradrenaline and dopamine reuptake inhibitor, bupropion, has been shown to significantly improve symptoms of energy, pleasure and interest in patients with depression with predominant baseline symptoms of decreased pleasure, interest and energy. Thus, there is a pattern of symptoms inadequately addressed by serotonergic antidepressants, suggesting treatments that enhance noradrenergic or dopaminergic activity may be more appropriate to certain types of TRD, such as depression with comorbid anxiety disorders or patients with predominant symptoms of fatigue  ADDIN EN.CITE (Nutt et al., 2007).

It is also becoming apparent that inflammatory processes can contribute to the pathogenesis of MDD. Patients with depression have been found to have increased levels of inflammatory cytokines in their circulation, which can interact with neurotransmitter and neuroendocrine pathways  ADDIN EN.CITE (Miller et al., 2009). Patients with MDD also show dysregulation of the hypothalamic–pituitary–adrenal axis, with increased cortisol levels, and changes in glutamate function  ADDIN EN.CITE (Miller et al., 2009). More recently, it has been suggested that TRD may be associated with excessive clearance of antidepressant drugs out of the brain, across the blood–brain barrier (Clarke et al., 2009).

Current treatment options
Several classes of therapeutic agents have demonstrated efficacy in the treatment of depression, either as monotherapy or in combination (Table 2). A number of national and international bodies have attempted to define frameworks or algorithms for the treatment of MDD, including TRD. The first attempt to prospectively develop and evaluate such algorithms was the Texas Medication Algorithm Project (TMAP), which convened an expert panel to develop treatment pathways for MDD with or without psychotic features (Crismon et al., 1999) (Table 3). Other published frameworks include those of the World Federation of Societies of Biological Psychiatry (WFSBP)  ADDIN EN.CITE (Bauer et al., 2002b; Bauer et al., 2002a), the Canadian Network for Mood and Anxiety Treatments (CANMAT) (Kennedy et al., 2009a) (Table 3), the British Association of Psychopharmacology  ADDIN EN.CITE (Anderson et al., 2008) and the Maudsley Prescribing Guidelines (Taylor et al., 2007). On the whole, however, current national guidelines for TRD   ADDIN EN.CITE (León, 1999; SOPSI, 1999; DGPPN, 2000; ANAES, 2002; AFSSAPS, 2006; Kasper and Lehofer, 2007; NICE, 2009) are often out of date. Furthermore, guidelines play an important role in primary care but are often less impactful in secondary and tertiary treatment of TRD. The situation is complicated by the fact that many patients with MDD are now treated initially in primary care, and thus have already experienced a lack of response to at least one first-line agent by the time they are seen by a psychiatrist (O'Reardon, 2009). Few, if any, antidepressants have been evaluated in clinical trials enrolling patients with TRD, and there is thus an evidence gap between the needs of patients and the available data. 

Pharmacological interventions
There is a long history of use of antidepressant drugs to treat MDD, and many clinical trials have confirmed their effectiveness. For example, a recent Cochrane library systematic review and meta-analysis of antidepressants in primary care concluded that tricyclic antidepressants and selective serotonin reuptake inhibitors are significantly more effective than placebo in treating MDD (Arroll et al., 2009). Moreover, prodromal symptoms have been identified in patients with unipolar and bipolar depression, and recognition of such symptoms by patients and their physicians may allow effective intervention to prevent relapse (Geddes, 2003). However, current treatment of MDD with SSRIs and serotonin noradrenaline reuptake inhibitors (SNRIs) is limited by modest response rates, slow onset of action and tolerability concerns  ADDIN EN.CITE (Kasper et al., 2006; Montgomery, 2008; Papakostas and Fava, 2009). A meta-analysis of 182 placebo-controlled trials of antidepressants (n=36,385) found that clinical response (defined as a 50% or greater reduction in HAM-D or MADRS score from baseline to endpoint, or a Clinical Global Impression of Improvement (CGI-I) score of <3 at the final visit) occurred in approximately 50% of all patients treated with antidepressants (Figure 8) (Papakostas and Fava, 2009). It should be noted, however, that the mean duration of studies included in the analysis was only 7 weeks.

One obvious course of action to treat TRD is to switch the patient to a different antidepressant, either to another example of the same drug class or to a drug with a different mechanism of action. Although the latter may seem, at first glance, to be the preferred option, there is no conclusive evidence to support switching out of class over switching within the class for SSRI non-responders (Lam et al., 2009). A meta-analysis of four clinical trials (n=1496) found only a modest, although statistically significant, advantage of switching to a non-SSRI (bupropion, mirtazapine, venlafaxine) in patients with SSRI-resistant depression (Papakostas et al., 2008). Pooled remission rates were 28% (for non-SSRIs) and 23.5% (for SSRIs), with a risk ratio of 1.29 (p=0.007) in favour of switching to a non-SSRI. In general, switching within the SSRI class can be achieved quickly, and is associated with an average response rate of around 50% (Thase, 2009). When a within-class SSRI switch was compared with a switch to mirtazapine, efficacy was similar after 8 weeks. The within-class switch was associated with slightly better tolerability, which may be explained by SSRI discontinuation symptoms in patients who were switched out of class. In patients with more severe TRD, a switch to an SNRI such as venlafaxine may have advantages (Thase, 2009). 

An alternative to switching to a different antidepressant is to combine antidepressants. Combination strategies best studied in TRD include combination of an SSRI or SNRI with a noradrenaline–dopamine reuptake inhibitor (e.g. bupropion) or a serotonin–noradrenaline antagonist (e.g. mirtazapine or mianserin), or combination of an SSRI with a tricyclic antidepressant (TCA) (e.g. desipramine) (Papakostas, 2009). In particular, preliminary studies have shown potential benefits of venlafaxine in combination with mirtazapine  ADDIN EN.CITE (Hannan et al., 2007; Malhi et al., 2008), whereas a more recent randomised controlled trial of mirtazapine in combination with fluoxetine, venlafaxine or bupropion compared with fluoxetine monotherapy found that the three combination therapies were associated with approximately double the remission rate of fluoxetine monotherapy (46–58% vs 25%)  ADDIN EN.CITE (Blier et al., 2010). However, consideration of combination regimens should also take into account the single-blind, prospective study by Rush et al, 2011 (Rush et al., 2011), which showed no difference in response or remission between treatment with escitalopram plus placebo, sustained-release bupropion plus escitalopram, or extended-release venlafaxine plus mirtazapine. 

Combining antidepressants is common practice in many countries, despite a small evidence base. Caution should also be taken when combining antidepressants to avoid pharmacokinetic or pharmacodynamic interactions (Schmauss and Messer, 2009). For example, combinations including monoamine oxidase inhibitors can cause serotonin syndrome, and some SSRIs, such as fluoxetine and paroxetine (both of which block CYP2D6), are associated with increased TCA levels in plasma, resulting in an increased risk of toxicity.

An alternative to combining two antidepressants is to augment antidepressant therapy with a different drug, and such augmentation strategies are among the best validated pharmacological treatments for TRD (Lam et al., 2009). Of the many possible strategies available, the combination of TCAs with lithium or triiodothyronin (T3) are the most extensively studied (Carvalho et al., 2009). Other adjunctive treatments studied include buspirone, pindolol, omega-3 fatty acids, atypical antipsychotics, stimulants (modafinil, atomoxetine), lamotrigine, folic acid, methylfolate and s-adenosylmethionine  ADDIN EN.CITE (Philip et al., 2010; Shelton et al., 2010). 

Evidence for lithium as an adjunctive therapy in patients with depressive disorders is, however, somewhat mixed. In a 6-week, randomised controlled trial in 35 patients whose depression did not respond to nortriptyline, for example, there was no statistically significant difference between lithium and placebo augmentation (Nierenberg et al., 2003). In a meta-analysis of 10 randomised, placebo-controlled studies (n=269) in which lithium was used to augment antidepressant therapy for patients with unipolar depression or bipolar disorder (depressive phase), lithium augmentation was found to be statistically significantly more effective than placebo (OR=3.11; 95% CI: 1.80–5.37) (Crossley and Bauer, 2007). Most of the trials were, however, of very short duration (2–3 weeks), and it is unclear how effective lithium augmentation is in the long term. Recently, lithium augmentation has been compared with T3 augmentation in the STAR*D trial in patients who had not achieved remission in two preceding treatment trials in the study  ADDIN EN.CITE (Nierenberg et al., 2006). Patients continued to receive citalopram, sertraline, bupropion or extended-release venlafaxine. After a mean of 9.6 weeks of treatment, remission rates were modest and not significantly different between those patients who received T3 augmentation (24.7%) and those who received lithium augmentation (15.9%). T3 augmentation was, however, associated with a lower side-effect burden and, together with improved ease of use compared with lithium treatment, may suggest a slight advantage of the T3 augmentation  ADDIN EN.CITE (Nierenberg et al., 2006). Although the efficacy of T3 augmentation of TCAs is more established  ADDIN EN.CITE (Aronson et al., 1996; Altshuler et al., 2001; Carvalho et al., 2009; Connolly and Thase, 2011), evidence for the efficacy of T3 augmentation of SSRIs is more disparate based on the available evidence  ADDIN EN.CITE (Nierenberg et al., 2006; Cooper-Kazaz and Lerer, 2008; Carvalho et al., 2009; Shelton et al., 2010). Further research is needed before the efficacy of T3 augmentation of the newer antidepressants can be definitively established (Cooper-Kazaz and Lerer, 2008). 

In recent years, there has been increasing interest in the use of certain atypical antipsychotic agents as adjunctive therapy in TRD. At a consensus meeting of the European College of Neuropsychopharmacology in 2008, the panel agreed that there was evidence to show that some atypical antipsychotics can induce remission when added to an antidepressant (usually a SSRI or SNRI) in patients with MDD unresponsive to antidepressant monotherapy (Goodwin et al., 2009). Although the precise mechanism of action of antipsychotic agents in depression is unclear, it appears that activity of atypical antipsychotics at 5HT receptors, including 1A, 2A and 2C subtypes, is associated with antidepressant effects (Stahl, 2000). At the time of publication, quetiapine extended-release tablets was the only atypical antipsychotic approved for use in MDD in Europe; their use has been approved as add-on to ongoing treatment in patients with a sub-optimal response to antidepressants (EMA, 2011). In the USA, aripiprazole is also indicated for the adjunctive treatment of MDD; olanzapine is indicated in combination with fluoxetine for TRD.

In the treatment of TRD, the available evidence for the use of atypical antipsychotic agents comes from case reports, small clinical trials and, more recently, large-scale projects. Although conflicting results have been produced, overall atypical antipsychotic augmentation shows promise (Shelton et al., 2010). When data from 16 trials of antipsychotic agents in MDD were pooled in a meta-analysis, antipsychotic treatment was found to be associated with significantly higher rates of response (OR=1.69; p<0.00001) and remission (OR=2.0; p<0.00001) than placebo (Nelson and Papakostas, 2009), although rates of discontinuation were also higher with adjunctive antipsychotic therapy (OR=3.91; p<0.00001) (Figure 9). This analysis, however, did not include trials of ziprasidone, paliperidone, asenapine and iloperidone, as double-blind studies have not yet been conducted. Data supporting the efficacy of aripiprazole augmentation in patients with TRD comes from three double-blind, placebo-controlled, 14-week trials  ADDIN EN.CITE (Berman et al., 2007; Marcus et al., 2008; Berman et al., 2009). Aripiprazole was superior to placebo in both response and remission rates, based on the clinician-rated MADRS, in all three trials. Data for quetiapine extended release showed significant improvements in MADRS total score over 6 weeks versus placebo  ADDIN EN.CITE (El-Khalili et al., 2010), and a significantly reduced risk of recurrence of a depressive event in a 52-week study of patients randomized to continue with quetiapine XR versus patients randomized to switch to placebo  ADDIN EN.CITE (Liebowitz et al., 2010). The data for ziprasidone in TRD are less robust and conflicting, with one positive  ADDIN EN.CITE (Papakostas et al., 2004) and one negative open-label trial  ADDIN EN.CITE (Dunner et al., 2007). 

For all the atypical antipsychotics, consideration of potential adverse events is important (Philip et al., 2010). Side effects can include metabolic perturbations and movement disorders, which can be debilitating, and the risk:benefit profile of antipsychotic augmentation should be carefully considered on an individual basis. Furthermore, research comparing antipsychotic augmentation with other augmentation strategies in TRD is also warranted. If atypical antipsychotics become more widely used for the treatment of MDD, negative associations with the word ‘antipsychotic’ or ‘neuroleptic’ could affect patient uptake, and an alternative drug class name could be useful (Klein et al., 2004).

Antidepressant augmentation has also been investigated with other pharmacological agents. Lamotrigine is an anticonvulsant drug that is used for the treatment of epilepsy and bipolar disorder and appears to be effective in the treatment of bipolar depression (Geddes et al., 2009). A certain degree of success has been observed with the augmentation of antidepressant therapy with lamotrigine in patients with TRD in a number of studies, including two open-label trials and one placebo-controlled trial  ADDIN EN.CITE (Barbosa et al., 2003; Gabriel, 2006; Schindler and Anghelescu, 2007). Furthermore, lamotrigine augmentation has been shown to have a comparable effect on response and remission compared with lithium augmentation in patients with TRD  ADDIN EN.CITE (Schindler and Anghelescu, 2007). However, the results of a placebo-controlled, randomised, double-blind study were not consistent with previous findings and showed no benefit of lamotrigine augmentation in combination with antidepressants compared with placebo (Santos et al., 2008). An analysis of the methodology of this latter study showed that doses of lamotrigine were maintained for less than 3 weeks due to the titration schedule. It is thought that lamotrigine has efficacy in depression via its activity as an inhibitor of presynaptic glutamate release (Philip et al., 2010).

Consideration of other pharmacological interventions in the treatment of TRD is ongoing. The role of glutamate in psychiatric illness is further highlighted by the recent studies of N-methyl-D-aspartate (NMDA) receptor antagonists in the treatment of TRD. An initial study with memantine was not encouraging  ADDIN EN.CITE (Zarate et al., 2006b); however, recent data from a study of intravenous ketamine have been more promising with further trials ongoing  ADDIN EN.CITE (Zarate et al., 2006a; aan het Rot et al., 2010; Philip et al., 2010). Other NMDA receptor antagonists, including intravenous CP-1101,606 and riluzole, have also shown some efficacy in the treatment of TRD albeit in very small numbers of patients  ADDIN EN.CITE (Sanacora and Saricicek, 2007; Preskorn et al., 2008). Other potential future treatments include nicotinic- and muscarinic-acetylcholine receptor-selective compounds such as scopolamine and mecamylamine (Philip et al., 2010). 

Given that inflammatory processes are postulated to be involved in the pathophysiology of depression  ADDIN EN.CITE (Miller et al., 2009), it is not surprising that studies are now being conducted that examine the effects of anti-inflammatory agents on depressive symptoms. Non-steroidal anti-inflammatory drugs (NSAIDs), such as celecoxib, aspirin and ibuprofen, are thought to possibly have some antidepressant activity  ADDIN EN.CITE (Muller et al., 2006; Muller and Schwarz, 2008) through their inhibition of the production of prostaglandins via cyclooxygenase pathways (Muller and Schwarz, 2008). Another agent worthy of mention for its antidepressant potential is the tetracycline antibiotic, minocycline; there is also some evidence that anti-inflammatory cytokines themselves may have antidepressant properties (Hayley, 2011). Both the NSAIDs and minocycline have demonstrated some efficacy in the augmentation of antidepressant treatment  ADDIN EN.CITE (Molina-Hernandez et al., 2008; Akhondzadeh et al., 2009). Similarly, given that HPA-axis dysfunction, particularly impaired glucocortocid receptor signalling, is evident in depression, agents that can address this could potentially have antidepressant effects (Juruena et al., 2004). In vitro studies have shown that SSRIs and TCAs have effects on glucocortocid receptors (Juruena et al., 2004). Whether anti-inflammatory agents will have a marked impact on TRD and the utility of redressing HPA-axis dysfunction in TRD is yet to be revealed.

Non-pharmacological interventions – stimulation strategies
Brain stimulation, unlike systemic pharmacology delivered orally or parenterally, focuses on direct or indirect alteration of brain function by electrical or magnetic methods (Schlaepfer et al., 2010). Such applied stimulation may be able to correct or positively influence underlying dysfunction. The archetypal stimulation therapy is ECT, which has consistently been shown to be highly effective for the treatment of depression  ADDIN EN.CITE (UK-ECT-Review-Group, 2003; Pagnin et al., 2004). Although relatively effective in MDD  ADDIN EN.CITE (Wijkstra et al., 2000; Frey et al., 2001), ECT is, however, less effective in patients with TRD compared with those who have responded to previous pharmacotherapy (Prudic et al., 1990). Furthermore, higher relapse rates have been observed in treatment-resistant versus non-resistant patients especially in the first months after treatment  ADDIN EN.CITE (Sackeim et al., 1990; Devanand et al., 1991). In order to minimise relapse, the use of pharmacotherapy or maintenance ECT may be beneficial  ADDIN EN.CITE (Wijkstra et al., 2000; McCall, 2001; Sackeim et al., 2001). ECT is often resisted by patients and their families because of fears of adverse effects, which are primarily related to cognitive impairments (Shelton et al., 2010), and has therefore generally become reserved for those with treatment-resistant disorders (Schlaepfer et al., 2010). There are now several new brain stimulation methods that provide alternatives to ECT.

Vagus nerve stimulation (VNS) therapy involves intermittent, repeated stimulation of the left vagus nerve in the neck, using a small electrical pulse from an implanted neurostimulator to a bipolar lead wrapped around the nerve  ADDIN EN.CITE (Kosel and Schlaepfer, 2002; Kosel and Schlaepfer, 2003). Recently, this approach has obtained a licence in the USA as an adjunctive treatment for TRD. Current knowledge suggests a place for VNS in the treatment of TRD; however, the evidence base is limited and the invasive nature of the treatment with its associated risks must be considered carefully (Daban et al., 2008). In multiple naturalistic studies, including long-term studies, VNS has demonstrated positive effects on symptomatology in patients with TRD (Daban et al., 2008). However, in the only randomised, controlled trial to date, the efficacy of VNS on TRD was inconclusive  ADDIN EN.CITE (Rush et al., 2005a). In this placebo-controlled trial of 235 patients, treatment with VNS did not show statistically significant antidepressant effects over a 10-week period compared with placebo treatment  ADDIN EN.CITE (Rush et al., 2005a). Retrospective analysis of this study has revealed that the patients were potentially under-dosed, receiving smaller amounts of stimuli than those generally administered in epilepsy (Daban et al., 2008). In the follow-up, 12-month naturalistic assessment of the original study by Rush et al., VNS in combination with ‘treatment-as-usual’ demonstrated statistically significantly higher response and remission rates  ADDIN EN.CITE (Rush et al., 2005b) compared with patients who received only treatment as usual  ADDIN EN.CITE (George et al., 2005). The side effects of VNS in this 12-month study were generally mild, occurred at the time of stimulation and included voice alteration, dyspnoea and neck pain  ADDIN EN.CITE (Rush et al., 2005b). 

Transcranial magnetic stimulation (TMS) is a new technique in which recent technology allows single, paired or repetitive magnetic pulses to be generated and delivered through the skull to stimulate cortical regions; normally, in the case of depression, the frontal cortex  ADDIN EN.CITE (George et al., 1997; George et al., 2000). The equipment for TMS has two parts: a stimulator, which generates brief pulses of strong electrical currents with a frequency and intensity that can be varied; and a stimulation coil connected to the stimulator. The magnetic field generated at the coil passes unimpeded through the scalp and skull, inducing an electric current in the underlying tissue, which in turn depolarises neurons  ADDIN EN.CITE (George et al., 2003; Schlaepfer and Kosel, 2004). The main advantage of this method of stimulation is its non-invasiveness and the possibility to stimulate relatively small brain volumes. Although some trials of TMS in depression have been positive, the overall tendency is one of limited efficacy and its role in TRD is uncertain (Martin et al., 2002). 

Recent advances in stereotaxic neurosurgical methods have provided a novel and promising technique for alleviating symptoms in psychiatric patients with well-characterised psychiatric disorders that are resistant to available interventions. Deep brain stimulation (DBS) has emerged as a widely recognised technology, having been developed initially to treat patients with Parkinson’s disease. DBS involves the MRI-guided stereotaxic placement of unilateral or bilateral electrodes in target brain regions connected to a permanently implanted neurostimulator, which electrically stimulates that brain region  ADDIN EN.CITE (Schlaepfer and Lieb, 2005; Schlapfer and Bewernick, 2009). Recently, this method has been demonstrated to have some effects in even the most treatment-resistant cases of depression in three independent, small studies  ADDIN EN.CITE (Malone et al., 2009; Bewernick et al., 2010). The majority of patients treated with DBS have a safe and effective outcome; however, potential side effects have been reported in patients with Parkinson’s disease (Voon et al., 2006), and the inherent risks must be considered and alternative therapies explored before DBS treatment is selected (Shelton et al., 2010).

In the study of DBS in TRD, three brain tissue targets have been more extensively studied – the subcallosal cingulate white matter, the ventral caudate/ventral striatum and the nucleus accumbens (Moreines et al., 2011). Response rates have been reported to be 40% and 60% after 6 months of treatment in patients treated with DBS of the ventral caudate/ventral striatum and subcallosal cingulate white matter, respectively, and 50% after 12 months of treatment in those who received DBS of the nucleus accumbens  ADDIN EN.CITE (Mayberg et al., 2005; Lozano et al., 2008; Malone et al., 2009; Bewernick et al., 2010). Encouragingly, cognitive side effects of the DBS of these three brain regions have been reported to be limited and, in some cognitive domains, improvements have been observed (Moreines et al., 2011). 

Non-pharmacological interventions – surgical strategies
Psychosurgery involves the creation of lesions in the frontolimbic circuits of the brain (Sachdev and Sachdev, 2005) and, as such, remains a last resort for patients with TRD after failure of standard treatments (Shelton et al., 2010). Psychosurgery is considered to be experimental; no significant new developments have been made in the last 30 years (Sachdev and Sachdev, 2005) and no gold standard has been established (Shelton et al., 2010). Several different neurological procedures have been more extensively evaluated in the treatment of depression, including subcaudate tractomy, anterior cingulatomy, limbic leucotomy and anterior capsulotomy (Sachdev and Sachdev, 2005). Although efficacy has been established in terms of symptom relief, only a small number of patients with TRD have been treated with psychosurgery, follow-up has generally been short-term (1–2 years) and the inherent risks of neurosurgery are very high  ADDIN EN.CITE (Shelton et al., 2010; Moreines et al., 2011). Longer-term outcomes have recently been reported in 23 patients with TRD after a mean of 14.4 years post-psychosurgery (Sachdev and Sachdev, 2005). Of these patients, 5 were reported to be in remission and 11 showed significant improvements in depressive symptomatology.  Complications of psychosurgery are profound and include epilepsy, irreversible personality changes and cognitive impairment  ADDIN EN.CITE (Sachdev and Sachdev, 2005; Moreines et al., 2011).

Non-pharmacological interventions – psychotherapy
Several different psychotherapies are used in the treatment of depressive disorders. Cognitive behavioural therapy (CBT) and interpersonal therapy (IPT) have the most evidence for efficacy to date. CBT is well studied, with more than 85 randomised controlled trials since 1977 providing empirical evidence for efficacy in the treatment of mild to moderate MDD. IPT has been recommended as a first-line option for acute MDD but there is insufficient evidence to ascertain its superiority or inferiority compared with CBT or pharmacological interventions (Parikh et al., 2009). In addition to a role in treatment of depression, psychotherapy may also be of value in the treatment of comorbidities, particularly anxiety disorders  ADDIN EN.CITE (Hunot et al., 2007; Schoevers et al., 2008).

Future directions for the treatment of TRD




The management of TRD in Europe is far from optimal and requires new approaches so that the goals of treatment – primarily remission – can be achieved. Indeed, the definition of TRD itself is not always consistent between studies or treatment guidelines, and a clear definition would go some way to refining treatment options. In addition, the definition of remission should be clearly defined, for physicians but also for patients, allowing expectations of therapeutic outcomes to be managed appropriately. Although many guidelines, frameworks and treatment algorithms have been developed, the appropriate sequence of treatment steps needs to become widely accepted so that it can be refined and adapted to individual patients. It might be that more focused, targeted treatment approaches that modulate specific networks in the brain will prove a more effective approach to help treatment-resistant patients. Overall, a thorough re-evaluation of TRD is needed to optimise long-term outcomes for patients.
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Table 1. Variables associated with treatment-resistant depression in a study of 702 patients  ADDIN EN.CITE (Souery et al., 2007) 





Early age of onset (<18 years)	2.0 (1.2–3.3)	0.009
Severe depression (vs moderate)	1.7 (1.2–2.3)	0.001
Personality disorder	1.7 (1.0–2.9)	0.049
Multiple hospitalisations (>1)	1.6 (1.2–2.1)	0.003
Non-response to first antidepressant	1.6 (1.1–2.5)	0.019








Table 2. Key drug classes available for the treatment of depression 
 ADDIN EN.CITE (Wakeling, 1983; Lotufo-Neto et al., 1999; Anderson, 2000; Baldessarini, 2001; Baldessarini and Tarazi, 2001; Stahl et al., 2005; Thase, 2008; Watanabe et al., 2008; Arroll et al., 2009; Nelson and Papakostas, 2009; Thase, 2009)
Drug class	Mode of action	Efficacy	Side effects	Safety issues
Monoamine oxidase inhibitors	Prevent breakdown of monoamine neurotransmitters	First clinically effective antidepressants developed in the 1950s	Sedation or behavioural excitationPostural hypotensionSustained resting elevations of diastolic blood pressure	Risk of life-threatening acute poisoning with overdose
Tricyclic antidepressants 	Inhibition of noradrenaline reuptakeInhibition of serotonin reuptake Blockade of various adrenergic and other receptors	Well established since the early 1960s	Muscarinic effects (dry mouth, gastrointestinal side-effects, dizziness, tachycardia, blurred vision, urinary retention)Cardiovascular side-effects (see safety issues)Weakness and fatigueConfusion and deliriumWeight gain	Cardiovascular toxicity (hypotension, tachycardia, prolonged conduction time, arrhythmias)Epileptic seizuresRisk of life-threatening acute poisoning with overdose
Selective serotonin reuptake inhibitors 	Inhibition of serotonin reuptake	Generally similar efficacy to TCAs (may be less effective than amitriptyline)	Nausea and vomitingDiarrhoeaHeadacheSexual dysfunction	
Serotonin–noradrenaline reuptake inhibitors	Inhibition of noradrenaline reuptakeInhibition of serotonin reuptake	May be more effective than SSRIs, although data are conflicting	NauseaDry mouthSweatingConstipationSexual dysfunction	Hypertension and cardiovascular toxicity (venlafaxine)
Serotonin–noradrenaline antagonists (mirtazapine)	Indirect enhancement of serotonin and noradrenaline release	Similar efficacy to TCAs and SSRIs	Sedation (resulting from histamine H1 receptor blockade)Weight gain Sexual dysfunction	
Noradrenergic and dopaminergic reuptake inhibitors (bupropion)	Enhance dopamine and noradrenaline	As SSRIs	Headache – nausea	Seizures
Atypical antipsychotics	Various effects at receptors, including serotonin, dopamine, noradrenaline, histamine and acetylcholine	Effective as augmentation to antidepressant therapy	Vary by agent, including some or all of:Weight gain and metabolic disturbancesMovement disordersEndocrine dysfunctionCardiovascular side effects	Vary by agent










TMAP – MDD without psychotic features (Crismon et al., 1999)	A clinical psychopharmacology consultation should be considered in treatment-resistant patientsAfter two different first-line monotherapy antidepressants, a third monotherapy from a different class or a combination of an SSRI and a TCA should be consideredIf there is no response to a third agent or combination, ECT should be considered
TMAP – MDD with psychotic features (Crismon et al., 1999)	A clinical psychopharmacology consultation should be considered in treatment-resistant patientsFirst-line treatment involves amoxapine, or an antidepressant plus an antipsychoticIf there is no response to a first-line TCA, another TCA should be triedIf there is no response to TCA-based treatment, ECT should be consideredIf ECT is unsuccessful, a previously untried first-line treatment should be prescribed with lithium or other augmenting agent
Canada
CANMAT  ADDIN EN.CITE (Kennedy et al., 2009b; Lam et al., 2009) 	Treatment options for TRD include adding an evidence-based psychotherapy, switching to a neurostimulation treatment such as ECT or TMS, and continuing with pharmacological strategiesPharmacological strategies include switching to a different antidepressant monotherapy, or adding another agent to the first antidepressantThere is emerging evidence that deep brain stimulation is effective for otherwise treatment-resistant depression, but this is currently an investigational approach
United Kingdom
BAP – Treatment following inadequate treatment response  ADDIN EN.CITE (Anderson et al., 2008)	Assess risk/benefit profile of next-step treatment options against the severity and risks of the patient’s depression, the degree of treatment resistance and past treatmentsPharmacological strategies for TRD include increase in antidepressant dose, switching to a different antidepressant monotherapy, or augmentation/combination therapy Psychological treatment options include addition of CBT to antidepressant treatment or use of evidence-based psychological or behavioural treatmentsPhysical treatment options for TRD include neurostimulation treatment such as ECT, VNS or TMS, ablative surgery and continuing with pharmacological strategies
Global
WFSBP –
acute treatment  ADDIN EN.CITE (Bauer et al., 2002a)	TRD frequently results from inadequate dosage and inappropriate length of treatment with antidepressants, or from insufficient use of the available therapeutic repertoire in cases of incomplete responseNumerous pharmacological and non-pharmacological augmentation strategies have been describedMost treatment-resistant patients can be helped substantially by rigorous treatment approachesTMS and VNS have shown some promising results, but data are limitedECT should be considered for ‘absolute’ treatment-resistant depression
WFSBP –
maintenance treatment  ADDIN EN.CITE (Bauer et al., 2002a)	Maintenance treatment of patients with recurrent depression who experience recurrences during prophylactic treatment with standard agents, e.g. lithium or antidepressants, is one of the most challenging issues in the treatment of these disordersCombining an antidepressant with lithium, combining lithium with carbamazepine, or combining two different antidepressants are among the possible options, as is adjunctive treatment with thyroid hormone in supraphysiological doses, but evidence for the efficacy of these combinations is limited












Figure 2. Possible influences of the noradrenaline, serotonin and dopamine pathways on symptoms in major depressive disorder (adapted from Nutt et al. 2007  ADDIN EN.CITE (Nutt et al., 2007))

Figure 3. Possible outcomes of treatment of major depressive disorder (Adapted from Stahl 2000 (Stahl, 2000), Cambridge University Press, with permission) 


Figure 4. Remission rates for various treatment steps in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study (Warden et al., 2007)

Figure 5. Antidepressant efficacy at every step of depression treatment (Reprinted from Kupfer 1991 (Kupfer, 1991); Copyright 2010, Physicians Postgraduate Press. Reprinted with permission)

Figure 6. Factors associated with resistance to antidepressant treatment  ADDIN EN.CITE (Souery et al., 2007)






Figure 8. Response rates with antidepressants and placebo in a pooled meta-analysis (Papakostas and Fava, 2009)


Figure 9. Rates of response, remission and discontinuation as a result of adverse events in a meta-analysis of 16 studies of antipsychotic augmentation in major depressive disorder












